News

By: Claire Sachs, Founder of the Patient Advocate’s Chronicle and a DPAC Champion Corps member Millions of Americans afflicted with...

The Senate Judiciary Committee held a hearing this week titled, “PBM Power Play: Examining Competition Issues in the Prescription Drug...

A recent report found that the dominance of pharmacy benefit managers (PBMs) in the 340B drug pricing program benefits these large...

In today’s healthcare landscape, few issues affect patient access and affordability as much as PBM practices. With 80% of the PBM market...

Millions of rural Americans face a devastating health crisis. They suffer from high rates of chronic diseases yet face a severe shortage...

Recent public financial disclosures from major health insurance conglomerates like CVS Health  have shed light on a concerning trend: the...

Last week, the House Energy and Commerce Committee’s Subcommittee on Health held a hearing entitled, “An Examination of How Reining in...

One employer was paying about $100 for a prescription for a generic antidepressant, though it could be bought elsewhere for about $12 A...

The New York Times  has published a detailed investigation  into how middlemen pharmacy benefit managers (PBMs) drive up drug costs for...

This is Part 1 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. Watch here >